LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company, announced that its stockholders have approved the merger with Alumis Inc. (Nasdaq: ALMS). At a special meeting held today, ACELYRIN stockholders voted in favor of the merger agreement, which stipulates that they will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. The merger aims to create a biopharma company dedicated to developing and commercializing transformative therapies for immune-mediated diseases. The transaction is expected to be completed in the second quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.